Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7300563 | 0.81 | USP2 (0.41) | USP2SMN1; SMN2ELANEGAARECQL | |
| SCHEMBL1931528 | 0.78 | ELANE (0.38) | USP2SMN1; SMN2ELANE | |
| SCHEMBL1931297 | 0.75 | ELANE (0.36) | ELANE | |
| SCHEMBL7299181 | 0.75 | ELANE (0.36) | ELANE | |
| SCHEMBL7308248 | 0.73 | ELANE (0.35) | ELANE | |
| SCHEMBL28132559 | 0.73 | ELANE (0.35) | ELANE | |
| SCHEMBL8263593 | 0.73 | USP2 (0.32) | USP2SMN1; SMN2 | |
| SCHEMBL17873088 | 0.73 | ELANE (0.36) | ELANEGAA | |
| SCHEMBL16050853 | 0.72 | ELANE (0.38) | ELANE | |
| SCHEMBL22886198 | 0.71 | ELANE (0.33) | ELANEGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403467-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2021-12-30 | — | — | US | disclosed |
| CN-107987075-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2020-12-01 | — | — | CN | disclosed |
| US-20200331907-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2020-10-22 | — | — | US | disclosed |
| EP-3415514-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180354952-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2018-12-13 | — | — | US | disclosed |
| US-10081628-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2018-09-25 | — | — | US | disclosed |
| EP-2970257-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20170008891-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2017-01-12 | — | — | US | disclosed |
| EP-2970257-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150299197-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2015-10-22 | — | — | US | disclosed |
| WO-2014158528-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275082-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |